Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor.
What have been key moves—capacity additions and acquisitions by CDMOs of drug substances (small molecules and biologics) thus far in 2026? A roundup of key developments.
CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide production capacity with newly-upgraded facilities at its Colorado site in the US, which the company says is the world's largest solid-phase peptide synthesis (SPPS) manufacturing facility.
CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is designed to provide innovative biotech and pharma customers with a fully integrated API to Drug Product service offering.
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International have launched a three-year project to accelerate the development of RNA-based drugs.
German CDMO CordenPharma, a specialist in Active Pharmaceutical Ingredients (APIs), excipients, drug products and packaging services (APIs), is investing more than €10 million in a new lipid nanoparticle (LNP) formulation, development and production area at its sterile injectable facility in Caponago, Italy.
Full-service CDMO CordenPharma is making a major investment to increase lipid manufacturing capacity at its CordenPharma Chenôve facility near Dijon, France. The project is one of 25 based on mRNA technology that the French government is backing with altogether €585 million.
Rumors that German pharmaceutical producer CordenPharma is up for sale have resurfaced following fresh reports that the company’s owner, International Chemical Investors Group (ICIG), plans to formally solicit bids for the business at the end of January.
German chemical company Wacker and compatriot CDMO CordenPharma have agreed to jointly develop know-how and processes for manufacturing lipid nanoparticles (LNP) to meet growing market demand. Both companies will first build up R&D capacities at their respective sites – Wacker in Amsterdam, the Netherlands, and CordenPharma in Caponago, Italy.
Reacting to recent growth in European domestic demand, Luxembourg-headquartered CordenPharma is expanding capacity for non-GMP peptides at its center of excellence for peptide process development and non-GMP manufacturing in Frankfurt, Germany.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
CordenPharma has expanded peptide manufacturing capacity at its GMP API facility in Boulder, Colorado, USA, to accommodate what it said is “a large spike in demand” for peptide APIs and to continue its overall growth strategy.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
